Literature DB >> 27314417

Yellow Fever in a Worker Returning to China from Angola, March 2016.

Yun Ling, Jun Chen, Qin Huang, Yunwen Hu, Aihong Zhu, Shanke Ye, Lie Xu, Hongzhou Lu.   

Abstract

Entities:  

Keywords:  Angola; China; flavivirus; vaccine; viruses; yellow fever; yellow fever virus

Mesh:

Substances:

Year:  2016        PMID: 27314417      PMCID: PMC4918156          DOI: 10.3201/eid2207.160469

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Yellow fever is disease caused by a flavivirus that is transmitted to humans and nonhuman primates through the bites of infected mosquitoes. In 2013, an estimated 130,000 persons in Africa experienced fever with jaundice or hemorrhage associated with yellow fever; ≈78,000 of these infections were fatal (). Recently, an outbreak of yellow fever was reported in Angola (). This serious viral disease affects persons living in and visiting tropical regions of Africa and Central and South America (). No case of yellow fever had been confirmed in China until this year (). With the increased population movement between Africa and China, the risk for yellow fever in China is increasing. In March 2016, a 34-year-old man who had recently returned to China from Angola sought medical treatment at the Shanghai Public Health Clinical Center in Shanghai, China. He reported a 4-day history of malaise, myalgia, weakness, nausea, vomiting, and fever reaching 38.8°C. The patient had been treated with several antimicrobial drugs when he was in Angola, but symptoms did not resolve. He had no history of immunodeficiency or immune-inhibitory drug use. No endocrine, metabolic, or autoimmune abnormalities were found. Nine years earlier, the patient had undergone cardiac valve replacement for rheumatoid heart disease and was currently receiving warfarin therapy. Because his treating physicians were concerned about the potential effect of yellow fever vaccine on the patient’s international normalized ratio (ratio of reference to measured prothrombin times), the patient traveled to Africa for work without receiving vaccination for yellow fever. Physical examination revealed a temperature of 37°C. Neither rash nor jaundice were evident. Blood examination revealed a low leukocyte count (1.66 × 109 cells/L [reference range 3.50–9.50 × 109 cells/L]), a low absolute lymphocyte count (0.92 × 109 cells/L [1.1–3.2 × 109 cells/L), a normal erythrocyte count (4.60 × 1012 cells/L [4.30–5.80 × 1012 cells/L]), and a low platelet count (43 × 109 platelets/L [125–350 × 109 platelets/L). The patient had low levels of circulating CD3+ cells (540/μL [690–2,540/μL) and CD8+ cells (97/μL [190–1,140/μL]) and normal levels of CD4+ T-cells. C-reactive protein level was 4.31 mg/L (reference range 0–3.0 mg/L), lactate dehydrogenase was 1,086 U/L (109–245 U/L), alanine aminotransferase was 882 U/L (7–40 U/L), total bilirubin was 13.5 μmol/L (0–17 μmol/L), and direct bilirubin was 7.4 μmol/L (0–5.4 μmol/L). The patient had normal levels of thyroid-stimulating hormone, and no DNA, nuclear, or thyroglobulin antibodies were detected. Test results for HIV, malaria, and dengue virus infection were negative. Serum and urine samples were positive for yellow fever virus and negative for dengue and Zika viruses by PCR. These results were confirmed by the Shanghai Center for Disease Control and Prevention and the China Center for Disease Control and Prevention. Yellow fever virus RNA remained detectable 9 days after symptom onset in serum and for an additional 3 days in urine and feces. A person from China traveling to a yellow fever–endemic area would usually receive vaccination against yellow fever (). Persons such as our patient, who cannot or should not receive vaccination for yellow fever, should be monitored closely. As of April 2, 2016, a total of 9 imported cases of yellow fever were reported in China: 4 cases in Fujian Province, 4 cases in Beijing, and 1 case in Shanghai. All 9 cases occurred in travelers returning to China from Angola; no local cases have been reported. The mosquito density is low in Shanghai, and the temperature typically is low in March, suggesting that the imported case we describe will probably not result in mosquito-borne transmission. However, in the upcoming summer, the risk for onward transmission of travel-associated yellow fever in China will warrant increased vigilance. To help prevent the importation and potential spread of yellow fever in China, the Chinese government now requests proof of vaccination for yellow fever from persons traveling to China from Angola.
  1 in total

1.  Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data.

Authors:  Tini Garske; Maria D Van Kerkhove; Sergio Yactayo; Olivier Ronveaux; Rosamund F Lewis; J Erin Staples; William Perea; Neil M Ferguson
Journal:  PLoS Med       Date:  2014-05-06       Impact factor: 11.069

  1 in total
  14 in total

1.  Rift Valley Fever Virus and Yellow Fever Virus in Urine: A Potential Source of Infection.

Authors:  Meng Li; Beibei Wang; Liqiang Li; Gary Wong; Yingxia Liu; Jinmin Ma; Jiandong Li; Hongzhou Lu; Mifang Liang; Ang Li; Xiuqing Zhang; Yuhai Bi; Hui Zeng
Journal:  Virol Sin       Date:  2019-03-19       Impact factor: 4.327

Review 2.  The continued threat of emerging flaviviruses.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Nat Microbiol       Date:  2020-05-04       Impact factor: 17.745

3.  Potential risk of re-emergence of urban transmission of Yellow Fever virus in Brazil facilitated by competent Aedes populations.

Authors:  Dinair Couto-Lima; Yoann Madec; Maria Ignez Bersot; Stephanie Silva Campos; Monique de Albuquerque Motta; Flávia Barreto Dos Santos; Marie Vazeille; Pedro Fernando da Costa Vasconcelos; Ricardo Lourenço-de-Oliveira; Anna-Bella Failloux
Journal:  Sci Rep       Date:  2017-07-07       Impact factor: 4.379

Review 4.  Mosquito-Associated Viruses in China.

Authors:  Han Xia; Yujuan Wang; Evans Atoni; Bo Zhang; Zhiming Yuan
Journal:  Virol Sin       Date:  2018-03-12       Impact factor: 4.327

5.  Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination.

Authors:  Michael Kongsgaard; Maria R Bassi; Michael Rasmussen; Karsten Skjødt; Søren Thybo; Mette Gabriel; Morten Bagge Hansen; Jan Pravsgaard Christensen; Allan Randrup Thomsen; Soren Buus; Anette Stryhn
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

Review 6.  Current Status of Dengue Therapeutics Research and Development.

Authors:  Jenny G H Low; Eng Eong Ooi; Subhash G Vasudevan
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

7.  French Aedes albopictus are able to transmit yellow fever virus.

Authors:  Fadila Amraoui; Marie Vazeille; Anna Bella Failloux
Journal:  Euro Surveill       Date:  2016-09-29

8.  Estimating the number of unvaccinated Chinese workers against yellow fever in Angola.

Authors:  A Wilder-Smith; E Massad
Journal:  BMC Infect Dis       Date:  2018-04-17       Impact factor: 3.090

9.  ChikDenMaZika Syndrome: the challenge of diagnosing arboviral infections in the midst of concurrent epidemics.

Authors:  Alberto E Paniz-Mondolfi; Alfonso J Rodriguez-Morales; Gabriela Blohm; Marilianna Marquez; Wilmer E Villamil-Gomez
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-07-22       Impact factor: 3.944

10.  Phylogenomic analysis unravels evolution of yellow fever virus within hosts.

Authors:  Chen Chen; Dong Jiang; Ming Ni; Jing Li; Zhihai Chen; Jingyuan Liu; Hanhui Ye; Gary Wong; Wei Li; Yuanyuan Zhang; Beibei Wang; Yuhai Bi; Danying Chen; Ping Zhang; Xuesen Zhao; Yaxian Kong; Weifeng Shi; Pengcheng Du; Gengfu Xiao; Juncai Ma; George F Gao; Jie Cui; Fujie Zhang; Wenjun Liu; Xiaochen Bo; Ang Li; Hui Zeng; Di Liu
Journal:  PLoS Negl Trop Dis       Date:  2018-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.